Malassezia fungemia, antifungal susceptibility testing and epidemiology of nosocomial infections

Malassezia and the Skin: Science and Clinical Practice

Volumn , Issue , 2010, Pages 229-251

  Tragiannidis, Athanasios ^c   Groll, Andreas ^d   Velegraki, Aristea ^a   Boekhout, Teun ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855504097     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-03616-3_8     Document Type: Chapter

References (101)

1. Barber GR, Brown AE, Kiehn TE et al (1993) Catheter-related Malassezia furfur fungemia in immunocompromised patients. Am J Med 95:365-370
2. Chryssanthou E, Broberger U, Petrini B (2001) Malassezia pachydermatis fungaemia in a neonatal intensive care unit. Acta Paediatr 90:323-327
3. Dankner WM, Spector SA, Fierer J et al (1987) Malassezia fungemia in neonates and adults: complication of hyperalimentation. Rev Infect Dis 9:743-753
4. Groll AH, Walsh TJ (2001) Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 7(suppl 2):8-24
5. Shattuck KE, Cochran CK, Zabransky RJ et al (1996) Colonization and infection associated with Malassezia and Candida species in a neonatal unit. J Hosp Infect 34:123-129
6. Redline RW, Dahms BB (1981) Malassezia pulmonary vasculitis in an infant on long-term intralipid therapy. N Engl J Med 305:1395-1398
7. Alpert G, Bell LM, Campos JM (1987) Malassezia furfur fungemia in infancy. Clin Pediatr 26:528-531
8. Aschner JL, Punsalang A, Maniscalo W et al (1987) Percutaneous central venous catheter colonization with Malassezia furfur: incidence and clinical significance. Pediatrics 80:535-539
9. Cannizzo FT, Eraso E, Ezkurra PA et al (2007) Biofilm development by clinical isolates of Malassezia pachydermatis. Med Mycol 45:357-361
10. Powell DA, Aungst J, Snedden S et al (1984) Broviac catheter-related Malassezia furfur sepsis in five infants receiving intravenous fat emulsions. J Pediatr 105:987-990
11. Redline RW, Redline SS, Boxerbaum B et al (1985) Systemic Malassezia furfur infections in patients receiving intralipid therapy. Hum Pathol 16:815-822
12. Chang HJ, Miller H, Watkins N et al (1998) An epidemic of Malassezia pachydermatis in an intensive care nursery associated with colonization of health care workers' pet dogs. New Engl J Med 338:706-711
13. Surmont I, Gavilanes A, Vandepitte J, et al (1989) Malassezia furfur fungaemia in infants receiving intravenous lipid emulsions. A rarity or just underestimated? Eur J Pediatr 148: 435-438
14. Welbel SF, McNeil MM, Pramanik A et al (1994) Nosocomial Malassezia pachydermatis bloodstream infections in a neonatal intensive care unit. Pediatr Infect Dis J 13:104-108
15. Morrison VA, Weisdorf DJ (2000) The spectrum of Malassezia infections in the bone marrow transplant population. Bone Marrow Transplant 26:645-648
16. Schleman KA, Tullis G, Blum R (2000) Intracardiac mass complicating Malassezia furfur fungemia. Chest 118:1828-1829
17. Schoepfer C, Carla H, Bezou MJ et al (1995) Malassezia furfur septicemia after bone marrow graft. Arch Pediatr 2:245-248
18. Shparago NI, Bruno PP, Bennett J (1995) Systemic Malassezia furfur infection in an adult receiving total parenteral nutrition. J Am Osteopath Assoc 6:375-377
19. Weiss SJ, Schoch PE, Cuhna BA (1991) Malassezia furfur fungemia associated with central venous catheter lipid emulsion infusion. Heart Lung 20:87-90
20. Masure O, Minoui A, Legall P et al (1997) Etude prospective de la colonisation des catheters vasculaires par les levures Malassezia. J Mycol Méd 7:33-36
21. Sizun J, Karangwa A, Giroux JD et al (1994) Malassezia furfur-related colonization and infection of central venous catheters. A prospective study in a pediatric intensive care unit. Intensive Care Med 20:496-499
22. Curvale-Fauchet N, Botterel F, Legrand P et al (2004) Frequency of intravascular catheter colonization by Malassezia spp. in adult patients. Mycoses 47:491-494
23. Bell LM, Alpert G, Slight PH et al (1985) Skin colonization of hospitalized and non-hospitalized infants with lipophilic yeasts. Abstr ICAAC 519 25th ICAAC, 29 September - 2 October, Minneapolis, Minnesota, USA
24. Ahtonen P, Lehtonen OP, Kero P et al (1990) Malassezia furfur colonization of neonates in an intensive care unit. Mycoses 33:543-547
25. Ashbee HR, Leck AK, Puntis JW et al (2002) Skin colonization by Malassezia in neonates and infants. Infect Control Hosp Epidemiol 23:212-216
26. Maki DG (1982) Infections associated with intravascular lines. In: Remington JS, Swartz MN (eds) Current clinical topics in infectious diseases, 3rd edn. McGraw-Hill, New York, pp 309-363
27. Van Belkum A, Boekhout T, Bosboom R (1994) Monitoring spread of Malassezia infections in a neonatal intensive care unit by PCR-mediated genetic typing. J Clin Microbiol 32: 2528-2532
28. Ashbee HR, Evans EG (2002) Immunology of diseases associated with Malassezia species. Clin Microbiol Rev 15:21-57
29. Powell DA, Marcon MJ, Durrell DE et al (1987) Scanning electron microscopy of Malassezia furfur attachment to Broviac catheters. Hum Pathol 18:740-745
30. Marcon MJ, Powell DA (1987) Epidemiology, diagnosis, and management of Malassezia furfur systemic infection. Diagn Microbiol Infect Dis 7:161-175
31. Marcon MJ, Durrell DE, Powell DA et al (1987) In vitro activity of systemic antifungal agents against Malassezia furfur. Antimicrob Agents Chemother 31:951-953
32. Pappas PG, Rex JH, Sobel JD et al (2004) Guidelines for treatment of candidiasis. Clin Infect Dis 38:161-189
33. Marcon MJ, Powell DA (1992) Human infections due to Malassezia spp. Clin Microbiol Rev 2:101-119
34. Shek YH, Tucker MC, Viciana AL et al (1989) Malassezia furfur disseminated infection in premature infants. Am J Clin Pathol 92:595-603
35. Devlin RK (2006) Invasive fungal infections caused by Candida and Malassezia species in them neonatal intensive care unit. Adv Neonatal Care 6:68-77
36. Zomorodian K, Mirhendi H, Tarazooie B et al (2008) Molecular analysis of Malassezia species isolated from hospitalized neonates. Pediatr Dermatol 25:312-316
37. Masure O, Leostic C, Abalain ML et al (1991) Malassezia furfur septicaemia in a child with leukaemia. J Infect 23:335-336
38. Middleton C, Lowenthal RM (1987) Malassezia furfur fungemia as a treatable cause of obscure fever in a leukemia patient receiving parenteral nutrition. Aust N Z J Med 17:603-604
39. Myers JW, Smith R, Youngberg G et al (1992) Fungemia due to Malassezia furfur in patients without the usual risk factors. Clin Infect Dis 14:620-621
40. Wurst RM, Knospe WN (1988) Malassezia furfur fungemia in a patient without the usual risk factors. Ann Intern Med 109:432-433
41. Kessler AT, Kourtis AP, Simon N (2002) Peripheral thromboembolism associated with Malassezia furfur sepsis. Pediatr Infect Dis J 21:356-357
42. Hassall E, Ulich T, Ament M (1983) Pulmonary embolus and Malassezia pulmonary infection related to urokinase therapy. J Pediatr 102:722-725
43. Ashbee HR (2007) Update on the genus Malassezia. Med Mycol 45:287-303
44. Kim E, Cohen RS, Ramachandran P et al (1993) Adhesion of percutaneously inserted Silastic central venous lines to the vein wall associated with Malassezia furfur infection. JPEN J Parenter Enteral Nutr 17:458-460
45. Nguyen ST, Lund CH, Durand DJ (2001) Thrombolytic therapy for adhesion of percutaneous central venous catheters to vein intima associated with Malassezia furfur Infection. J Perinatol 21:331-333
46. Rosales CM, Jackson MA, Zwick D (2004) Malassezia furfur meningitis associated with total parenteral nutrition subdural effusion. Pediatr Dev Pathol 7:86-90
47. Nelson SC, Yau YC, Richardson SE et al (1995) Improved detection of Malassezia species in lipid-supplemented Peds Plus blood culture bottles. J Clin Microbiol 33:1005-1007
48. Gaitanis G, Velegraki A, Frangoulis E et al (2002) Identification of Malassezia species from patient skin scales by PCR-RFLP. Clin Microbiol Infect 8:162-173
49. Tirodker U, Nataro J, Smith S et al (2003) Detection of fungemia by polymerase chain reaction in critically ill neonates and children. J Perinatol 23:117-122
50. Garau M, Pereiro M Jr, del Palacio A (2003) In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds. Antimicrob Agents Chemother 47:2342-2344
51. Gupta AK, Kohli Y, Li A et al (2000) In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine. Br J Dermatol 142:758-765
52. Miranda KC, de Araujo CR, Costa CR et al (2007) Antifungal activities of azole agents against the Malassezia species. Int J Antimicrob Agents 29:281-284
53. Prado MR, Brito EH, Brilhante RS et al (2008) Subculture on potato dextrose agar as a complement to the broth microdilution assay for Malassezia pachydermatis. J Microbiol Methods 75:341-343
54. Richet HM, McNeil MM, Edwards MC et al (1989) Cluster of Malassezia furfur pulmonary infections in infants in a neonatal intensive-care unit. J Clin Microbiol 27:1197-1200
55. Dimopoulos G, Velegraki A, Falagas ME (2009) A 10-year survey on antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. Antimicrob Agents Chemother 53:1242-1244
56. CLSI (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard M27-A3. In: Wayne PA (ed) Clinical and laboratory standards institute, 3rd edn, vol 28, No 14
57. EUCAST Definitive Document ED ef 7.1 (2008) Method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). Clin Microbiol Infect 14:398-405
58. Barbanoj MJ, Antonijoan R, Gea G et al (2005) Eberconazole cream: topical and general tolerability, sensitization potential and systemic availability. Methods Find Exp Clin Pharmacol 27:227-234
59. Koga H, Nanjoh Y, Makimura K et al (2008) In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol 29:1-8
60. Rubin AI, Bagheri B, Scher RK (2002) Six novel antimycotics. Am J Clin Dermatol 3:71-81
61. Uchida K, Nishiyama Y, Yamaguchi H (2004) In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother 10:216-219
62. Faergemann J (1989) A new model for growth and filament production of Pityrosporum ovale (orbiculare) on human stratum corneum in vitro. J Invest Dermatol 92:117-119
63. Velegraki A, Alexopoulos EC, Kritikou S et al (2004) Use of fatty acid RPMI 1640 media for testing susceptibilities of eight Malassezia species to the new triazole posaconazole and to six established antifungal agents by a modified NCCLS M27-A2 microdilution method and Etest. J Clin Microbiol 42:3589-3593
64. Nenoff P, Haustein UF (1997) In vitro susceptibility testing of Malassezia furfur against rilopirox. Skin Pharmacol 10:275-280
65. Nenoff P, Reinl P, Haustein UF (2001) The yeast fungus Malassezia: pathogen, pathogenesis and therapy. Hautarzt 52:73-86
66. Rukayadi Y, Hwang JK (2007) In vitro anti-Malassezia activity of xanthorrhizol isolated from Curcuma xanthorrhiza Roxb. Lett Appl Microbiol 44:126-130
67. Weseler A, Geiss HK, Saller R et al (2002) Antifungal effect of Australian tea tree oil on Malassezia pachydermatis isolated from canines suffering from cutaneous skin disease. Schweiz Arch Tierheilkd 144:215-221
68. Nakamura A, Kano A, Murai T et al (2000) Susceptibility testing of Malassezia species using the urea broth microdilution method. Antimicrob Agents Chemother 44:2185-2186
69. Rincón S, Cepero de García MC, Espinel-Ingrof A (2006) A modified Christensen's urea and CLSI broth microdilution method for testing susceptibilities of six Malassezia species to voriconazole, itraconazole, and ketoconazole. J Clin Microbiol 44:3429-3431
70. Brito EHS, Fontenelle ROS, Brilhante RSN et al (2007) In vitro activity of an ear rinse containing tromethamine, EDTA, benzyl alcohol and 0.1% ketoconazole on Malassezia organisms from dogs with otitis externa. Vet Dermatol 18:115-119
71. Brito EHS, Fontenelle ROS, Brilhante RSN et al (2007) Phenotypic characterization and in vitro antifungal sensitivity of Candida spp. and Malassezia pachydermatis strains from dogs. Vet J 174:147-153
72. Gupta AK, Plott T (2004) Ciclopirox: a broad-spectrum antifungal with antibacterial and anti-inflammatory properties. Int J Dermatol 43(Suppl 1):3-8
73. He SM, Du WD, Yang S et al (2008) The genetic epidemiology of tinea versicolor in China. Mycoses 51:55-62
74. Plewig G, Jansen T(1999) Seborrheic dermatitis. In: Freedberg IM, Eisen AZ, Wolff K et al (eds) Fitzpatrick's dermatology in general medicine. McGraw-Hill, New York, pp 1482-1489
75. Borgers M, Degreef H (2007) The role of ketoconazole in seborrheic dermatitis. Cutis 80: 359-363
76. Swinney A, Fazakerley J, McEwan N et al (2008) Comparative in vitro antimicrobial efficacy of commercial ear cleaners. Vet Dermatol 19:373-379
77. Kokjohn K, Bradley M, Griffiths B et al (2003) Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria. Int J Dermatol 42(suppl 1):11-17
78. Abeck D (2004) Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis: Results of a double-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage. Int J Dermatol 43(suppl 1):13-16
79. Lebwohl M, Plott T (2004) Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: Results of a double-blind, vehiclecontrolled trial. Int J Dermatol 43(suppl 1):17-20
80. Hammer KA, Carson CF, Riley TV (2000) In vitro activities of ketoconazole, econazole, miconazole, and Melaleuca alternifolia (tea tree) oil against Malassezia species. Antimicrob Agents Chemother 44:467-469
81. Sidrim JJC, Rocha MFG (1007) Phenotypic characterization and in vitro antifungal sensitivity of Candida spp. and Malassezia pachydermatis strains from dogs. Vet J 174:147-153
82. Nenoff P, Haustein UF, Brandt W (1996) Antifungal activity of the essential oil of Melaleuca alternifolia (tea tree oil) against pathogenic fungi in vitro. Skin Pharmacol 9:388-394
83. López-García B, Lee PHA, Gallo RL (2006) Expression and potential function of cathelicidin antimicrobial peptides in dermatophytosis and tinea versicolor. J Antimicrob Chemother 57:877-882
84. Piérard-Franchimont C, Ausma J, Wouters L et al (2005) Activity of the triazole antifungal R126638 as assessed by corneofungimetry. Skin Pharmacol Physiol 19:50-56
85. Piérard GE, Ausma J, Henry F et al (2007) A pilot study on seborrheic dermatitis using pramiconazole as a potent oral anti-Malassezia agent. Dermatology 214:162-169
86. Piérard-Franchimont C, Vroome V, Cauwenbergh G et al (2005) Corneofungimetry bioassay on Malassezia spp. under ketoconazole and desonide influences. Skin Pharmacol Physiol 18:98-102
87. Sugita T, Tsubuku H, Tajima M et al (2006) Time-kill assay of itraconazole against Malassezia species. Microbiol Immun 50:625-627
88. Pietschmann S, Hoffmann K, Voget M et al (2009) Synergistic effects of miconazole and polymyxin B on microbial pathogens. Vet Res Commun 33:489-505
89. Faergemann J, Ausma J, Borgers M (2006) In vitro activity of R126638 and ketoconazole against Malassezia species. Acta Derm Venereol 86:312-315
90. Sancak B, Ayhan M, Karaduman A et al (2005) In vitro activity of ketoconazole, itraconazole and terbinafine against Malassezia strains isolated from neonates. Mikrobiyol Bul 39: 301-308
91. Murai T, Nakamura Y, Kano R et al (2002) Susceptibility testing of Malassezia pachydermatis using the urea broth microdilution method. Mycoses 28:84-87
92. Arrese JE, Fogouang L, Piérard-Franchimont C et al (2002) Euclidean and fractal computerassisted corneofungimetry: A comparison of 2% ketoconazole and 1% terbinafine topical formulations. Dermatol 204:222-227
93. Brito EHS, Fontenelle ROS, Brilhante RSN, et al (2009) The anatomical distribution and antimicrobial susceptibility of yeast species isolated from healthy dogs. Vet J 182:320-326
94. Boekhout T, Bosboom R (1994) Karyotyping of Malassezia yeasts: taxonomic and epidemiological implications. Syst Appl Microbiol 17:146-153
95. Theelen B, Silvestri M, Guého E et al (2001) identification and typing of Malassezia yeasts using amplified fragment length polymorphism (AFLP), random amplified polymorphic DNA (RAPD) and denaturing gradient gel electrophoresis (DGGE). FEMS Yeast Res 1:79-86
96. Bougnoux ME, Tavanti A, Bouchier C et al (2003) Collaborative consensus for optimized multilocus sequence typing of Candida albicans. J Clin Microbiol 41:5265-5266
97. Cliff PR, Sandoe JA, Heritage J et al (1008) Use of multilocus sequence typing for the investigation of colonisation by Candida albicans in intensive care unit patients. J Hosp Infect 69:24-32
98. Jacobsen MD, Gow NA, Maiden MC et al (2007) Strain typing and determination of population structure of Candida krusei by multilocus sequence typing. J Clin Microbiol 45:317-323
99. Jacobsen MD, Boekhout T, Odds FC (2008) Multilocus sequence typing confirms synonymy but highlights differences between Candida albicans and Candida stellatoidea. FEMS Yeast Res 8:764-770
100. Maiden MC, Bygraves JA, Feil E et al (1998) Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 95:3140-3145
101. Tavanti A, Davidson AD, Johnson EM et al (2005) Multilocus sequence typing for differentiation of strains of Candida tropicalis. J Clin Microbiol 43:5593-5600